Glax­o­SmithK­line and Vir sub­mit Covid-19 mAb for emer­gency au­tho­riza­tion

As the US con­tin­ues to mon­i­tor the im­pact of vari­ants on au­tho­rized mon­o­clon­al an­ti­bod­ies (mAbs) and shake up which mAbs are dis­trib­uted where, Glax­o­SmithK­line and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.